Aviragen Therapeutics (AVIR) Tops Q3 EPS by 6c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q3 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Apple announced foldable iPhone Duo, starting at $1,999
• Copper Quest closes C$850,000 private placement led by Concept Capital
• Sprouts Farmers Market (SFM) call put ratio 8.7 calls to 1 put with a focus on 5400 contracts of January 110 calls as share price down 2.2%